[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640944":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":32,"responsibleParty":177,"collaborators":19,"id":179,"slug":180,"hasResults":181,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":181,"sex":187,"minAge":188,"maxAge":19,"enrollmentInfo":189,"targetDuration":19,"studyType":192,"phases":193,"briefSummary":195,"conditions":196,"keywords":19,"overallStatus":35,"whyStopped":19,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":209},{"fullName":5,"class":6},"Hoffmann-La Roche","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Mosunetuzumab","EXPERIMENTAL","Participants will receive mosunetuzumab by subcutaneous (SC) injection.",[13],"Drug: Mosunetuzumab",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Participants will receive SC mosunetuzumab.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Clinical Trials","STUDY_DIRECTOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Reference Study ID Number: GA45799 https:\u002F\u002Fforpatients.roche.com\u002F No attachments to email below.","CONTACT","888-662-6728 (U.S. Only)","global-roche-genentech-trials@gene.com",{"name":31,"role":27,"phone":19,"phoneExt":19,"email":19},"Fastest response: use the inquiry form. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",[33,47,57,62,72,82,87,95,106,115,124,136,146,158,168],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":19},"Clnica SER da Bahia","RECRUITING","Salvador","Estado de Bahia","40150-150","Brazil","BR",{"type":42,"coordinates":43},"Point",[44,45],-38.49096,-12.97563,{"lat":45,"lon":44},{"facility":48,"status":35,"city":49,"state":50,"zip":51,"country":39,"countryCode":40,"cosmosGeoPoint":52,"geoPoint":56,"contacts":19},"L2IP ?Instituto de Pesquisas Clínicas Ltda.","Brasília","Federal District","70200-730",{"type":42,"coordinates":53},[54,55],-47.92972,-15.77972,{"lat":55,"lon":54},{"facility":58,"status":35,"city":59,"state":60,"zip":61,"country":39,"countryCode":40,"cosmosGeoPoint":19,"geoPoint":19,"contacts":19},"IPC MT Instituto de Pesquisas Clinicas do Mato Grosso","Cuiab","Mato Grosso","78020-500",{"facility":63,"status":35,"city":64,"state":65,"zip":66,"country":39,"countryCode":40,"cosmosGeoPoint":67,"geoPoint":71,"contacts":19},"Complexo Hospitalar de Niteroi","Niterói","Rio de Janeiro","24030-103",{"type":42,"coordinates":68},[69,70],-43.10361,-22.88333,{"lat":70,"lon":69},{"facility":73,"status":35,"city":74,"state":75,"zip":76,"country":39,"countryCode":40,"cosmosGeoPoint":77,"geoPoint":81,"contacts":19},"LMK Servios Mdicos S\u002FS Ltda","Porto Alegre","Rio Grande do Sul","90480-000",{"type":42,"coordinates":78},[79,80],-51.23019,-30.03283,{"lat":80,"lon":79},{"facility":83,"status":35,"city":84,"state":85,"zip":86,"country":39,"countryCode":40,"cosmosGeoPoint":19,"geoPoint":19,"contacts":19},"Hospital das Clinicas de Ribeirao Preto","Ribeiro Preto","São Paulo","14048-900",{"facility":88,"status":35,"city":85,"state":85,"zip":89,"country":39,"countryCode":40,"cosmosGeoPoint":90,"geoPoint":94,"contacts":19},"Hospital das Clnicas da Faculdade de Medicina da USP","05403-000",{"type":42,"coordinates":91},[92,93],-46.63611,-23.5475,{"lat":93,"lon":92},{"facility":96,"status":35,"city":97,"state":19,"zip":98,"country":99,"countryCode":100,"cosmosGeoPoint":101,"geoPoint":105,"contacts":19},"Clinica de la Costa S.A.S","Barranquilla","080020","Colombia","CO",{"type":42,"coordinates":102},[103,104],-74.78132,10.96854,{"lat":104,"lon":103},{"facility":107,"status":35,"city":108,"state":19,"zip":109,"country":99,"countryCode":100,"cosmosGeoPoint":110,"geoPoint":114,"contacts":19},"Centro de Investigacion en Reumatologia y Especialdades Medicas SAS. CIREEM","Bogotá","110221",{"type":42,"coordinates":111},[112,113],-74.08175,4.60971,{"lat":113,"lon":112},{"facility":116,"status":35,"city":117,"state":19,"zip":118,"country":99,"countryCode":100,"cosmosGeoPoint":119,"geoPoint":123,"contacts":19},"Hospital Pablo Tobon Uribe","Medellín","050034",{"type":42,"coordinates":120},[121,122],-75.57151,6.245,{"lat":122,"lon":121},{"facility":125,"status":35,"city":126,"state":127,"zip":128,"country":129,"countryCode":130,"cosmosGeoPoint":131,"geoPoint":135,"contacts":19},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","Rome","Lazio","00168","Italy","IT",{"type":42,"coordinates":132},[133,134],12.51133,41.89193,{"lat":134,"lon":133},{"facility":137,"status":35,"city":138,"state":139,"zip":140,"country":129,"countryCode":130,"cosmosGeoPoint":141,"geoPoint":145,"contacts":19},"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)","Brescia","Lombardy","25123",{"type":42,"coordinates":142},[143,144],10.21472,45.53558,{"lat":144,"lon":143},{"facility":147,"status":35,"city":148,"state":149,"zip":150,"country":151,"countryCode":152,"cosmosGeoPoint":153,"geoPoint":157,"contacts":19},"Emmed Research","Pretoria","Gauteng","0002","South Africa","ZA",{"type":42,"coordinates":154},[155,156],28.18783,-25.74486,{"lat":156,"lon":155},{"facility":159,"status":35,"city":160,"state":161,"zip":162,"country":151,"countryCode":152,"cosmosGeoPoint":163,"geoPoint":167,"contacts":19},"University of Cape Town Kidney and Hypertension Research Unit","Cape Town","Western Cape","7925",{"type":42,"coordinates":164},[165,166],18.42322,-33.92584,{"lat":166,"lon":165},{"facility":169,"status":35,"city":170,"state":161,"zip":171,"country":151,"countryCode":152,"cosmosGeoPoint":172,"geoPoint":176,"contacts":19},"Clinical Trials Network Helderberg","Somerset West","7130",{"type":42,"coordinates":173},[174,175],18.82113,-34.08401,{"lat":175,"lon":174},{"type":178,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100640944","phase-2-a-study-to-evaluate-mosunetuzumab-in-participants-with-systemic-lupus-erythematosus-with-or-without-active-lupus-nephritis-100640944",false,"NCT07598396","A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis","A Phase II Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Mosunetuzumab in Patients With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis","SOLUNA","Inclusion Criteria:\n\n* Diagnosis of SLE for ≥ 6 months as assessed using the 2019 European League Against Rheumatism\u002FAmerican College of Rheumatology (EULAR\u002FACR) Classification Criteria at screening\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required\n* Treatment with investigational therapy within 30 days or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment and during the study\n* Major surgery requiring hospitalization during the 4 weeks prior to screening or during screening, or any planned surgery or procedure requiring hospitalization during the 12 weeks following study drug administration\n* Alcohol or substance abuse within the 12 months prior to screening\n* Active infection of any kind, excluding fungal infection of the nail beds\n* Any major episode of infection as defined by the protocol\n* History of serious recurrent or chronic infection\n* History of progressive multifocal leukoencephalopathy (PML)\n* Tuberculosis (TB) infection\n* History of cancer, including solid tumors, hematological malignancies, and carcinoma in situ, within the past 5 years\n* Active overlap syndrome with mixed connective tissue disease or systemic sclerosis within the 12 months prior to screening or during screening\n* Catastrophic or severe antiphospholipid syndrome within the 12 months prior to screening or during screening. Antiphospholipid syndrome adequately controlled by anticoagulant therapy for at least 2 months prior to screening is acceptable\n* High risk for clinically significant bleeding or any condition requiring plasmapheresis, IV immunoglobulin, or acute blood product transfusions\n* Active severe or unstable lupus-associated neuropsychiatric disease or where, in the opinion of the investigator, it is likely to require treatment with protocol-disallowed therapies. Examples of neuropsychiatric SLE manifestations include, but are not limited to the following: meningitis, retinitis, cerebral vasculitis, myelopathy, demyelination syndromes, acute confusional state, psychosis, acute stroke or stroke syndrome, cranial neuropathy, status epilepticus or seizures, cerebellar ataxia, and mononeuritis multiplex\n* History of any non-SLE disease treated with oral, intravenous, or intramuscular corticosteroids for more than 14 days in total during the one year prior to Day 1\n* History of treatment with any T cell-engaging bispecific antibodies or CAR-T therapy within the past 2 years\n* Receipt of any live or attenuated vaccine in the 28 days prior to or during screening","ALL","18 Years",{"count":190,"type":191},30,"ESTIMATED","INTERVENTIONAL",[194],"PHASE2","This study will assess how mosunetuzumab works in people who have systemic lupus erythematosus (SLE) who may or may not also have active lupus nephritis (LN).",[197,198,199],"Lupus","Systemic Lupus Erythematosus","Lupus Nephritis","2026-06-26",{"date":202,"type":203},"2026-06-30","ACTUAL",{"date":205,"type":203},"2026-05-25",{"date":207,"type":191},"2028-08-31",{"name":5,"class":6},15]